Today: 7 February 2026
Subscribe
Browse Category

Pharma Industry News 18 December 2025 - 28 December 2025

Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

NEW YORK, Dec. 27, 2025, 8:26 PM ET — Market closed Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is heading into the weekend with investors weighing a sharp Friday pullback against a still-staggering multi-month run, a cluster of insider-trading filings, and a set of analyst price targets that continue to imply significant upside—if Olema’s late-stage breast cancer program delivers on its timeline. With U.S. equity markets closed Saturday and Sunday, the next meaningful price discovery for OLMA will come when regular trading resumes Monday, Dec. 29, at 9:30 a.m. ET. New York Stock Exchange OLMA stock price today: where Olema closed, and
28 December 2025
·····
CSL Limited Stock (ASX: CSL) on 25 December 2025: Share Price, Buyback Momentum, Seqirus Uncertainty, and the 2026 Outlook

CSL Limited Stock (ASX: CSL) on 25 December 2025: Share Price, Buyback Momentum, Seqirus Uncertainty, and the 2026 Outlook

CSL Limited has spent 2025 doing something investors rarely enjoy watching in real time: a full-scale strategic reset—complete with restructuring, a wavering plan to separate its vaccines business, and a market that has been ruthlessly impatient. As of 25 December 2025 (Christmas Day), Australian markets are closed, so the best “today” snapshot for CSL Limited stock is the last ASX trading session (24 December 2025). CSL ended that session at A$171.48, down 2.38% on the day, after trading between A$171.48 and A$175.82. Investing That price level matters because it captures the whole mood: CSL is still widely viewed as a
25 December 2025
·····
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

NEW YORK — Pfizer Inc. (NYSE: PFE) is heading into the year-end stretch with investors juggling two competing storylines: near-term pressure from fading COVID-era sales and looming patent expirations, versus a long-term rebuild powered by oncology, internal medicine, and a refreshed pipeline strategy. In holiday-thinned trading on December 24, 2025, Pfizer shares were around $24.93. That “mid‑$20s” level matters because it has become the market’s psychological waiting room: bulls see a discounted global pharma franchise with a large dividend and multiple pipeline shots on goal; bears see a company still searching for its next era-defining growth engine. What’s moving Pfizer
24 December 2025
·····
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

December 24, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending 2025 with the kind of chart action that makes both traders and long-term biotech investors sit up straight. After a sharp multi-day run, Moderna stock pulled back hard: shares closed at about $32.29 on Dec. 23, down ~7.48% on the day, and were indicated around $32.11 in pre-market trading on Dec. 24. StockAnalysis That drop matters—but so does the context. The pullback follows a late-December surge that coincided with multiple headlines touching Moderna’s near-term product story (respiratory vaccines), its longer-term optionality (oncology and next-gen platforms), and its financial runway (new
24 December 2025
·····
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended Tuesday, December 23, 2025, slightly lower in regular trading, then steadied after the closing bell as investors digested a fresh legal headline tied to U.S. drug pricing—plus a growing list of end‑of‑year catalysts that could shape sentiment into 2026. BMY finished the session at $54.26, down $0.41 (-0.74%), and traded modestly higher in extended hours at about $54.36 (+0.20%) as of the evening update. MarketBeat After-hours snapshot: where BMY stands tonight Even with the post-close bounce, Tuesday’s tape looked like a classic pre-holiday setup: a narrow move, lighter conviction, and investors focusing more on
24 December 2025
·····
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

December 23, 2025 — Eli Lilly and Company (NYSE: LLY) is trading around $1,076 as investors digest a fresh competitive jolt in the obesity-drug race: the FDA has approved Novo Nordisk’s first daily oral version of Wegovy. The headline is about Novo, but the market’s real question is about Lilly’s moat: can LLY keep dominating the category while a new “pill era” starts to form? Reuters+1 Why Eli Lilly stock is in focus today: the FDA just green-lit the first oral Wegovy On December 23, Novo Nordisk won U.S. approval for a 25 mg oral Wegovy pill (semaglutide) for chronic
23 December 2025
······
Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

December 21, 2025 — Gilead Sciences, Inc. (NASDAQ: GILD) heads into a holiday-shortened trading week with an unusually dense mix of policy headlines and pipeline momentum—two forces that can quickly reprice a large-cap biopharma stock even when overall market volume is thin. Gilead ended the most recent session around $124.29, a level investors will treat as the near-term “line in the sand” as markets navigate Christmas week liquidity, fresh U.S. drug-pricing agreements, and renewed optimism around Gilead’s HIV franchise. Below is a week-ahead, publication-ready briefing on the latest Gilead news, forecasts, and market analysis as of Dec. 21, 2025, and
21 December 2025
····
CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited (ASX: CSL) heads into the final stretch of 2025 with its share price still under pressure—but with a growing stack of “things that matter” piling up beneath the surface: a sizeable on‑market buyback steadily absorbing stock, a major US manufacturing investment designed to reinforce its plasma-therapy moat, and a high-profile strategic reset that’s trying to simplify a complex, three‑engine biotech into something the market can price with less guesswork. As of the most recent trading day (Friday, 19 December 2025), CSL shares closed at A$175.08, after a volatile month that saw the stock slide from the mid‑A$180s toward
21 December 2025
·····
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

December 20, 2025 — AbbVie Inc. (NYSE: ABBV) is closing out the week in the spotlight as U.S. drug-pricing policy headlines collide with a still-strong “post-Humira” growth narrative built around Skyrizi and Rinvoq. The stock finished the last regular session (Friday, Dec. 19) at $226.82, up 1.80%, while trading volume surged well above its recent average — a sign that investors were repositioning into large-cap pharma after a rapid sequence of Washington announcements. MarketWatch Below is a full roundup of what’s driving AbbVie stock right now (as of 20.12.2025), what analysts are forecasting, and which catalysts could matter most heading
20 December 2025
·····
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson (NYSE: JNJ) is back on investors’ radar on Friday, December 19, 2025, as Wall Street digests a fast-moving mix of Washington drug-pricing headlines, a string of U.S. FDA decisions across pharma and medtech, ongoing talc litigation, and a wave of updated analyst price targets. JNJ shares traded around $208 intraday, hovering near the flatline as the market weighed policy risk against company-specific catalysts. MarketScreener Below is what’s driving the Johnson & Johnson stock narrative today—and what investors will be watching next. Why Johnson & Johnson stock is in the spotlight on Dec. 19, 2025 1) Drug-pricing pressure
19 December 2025
·····
Abbott India Share Price Today (19 December 2025): ABBOTINDIA Stock in Focus as Pharma Rally Meets Fresh Targets, Trading-Window Update and Q2 Results

Abbott India Share Price Today (19 December 2025): ABBOTINDIA Stock in Focus as Pharma Rally Meets Fresh Targets, Trading-Window Update and Q2 Results

Mumbai, December 19, 2025 — Abbott India Limited’s stock (NSE: ABBOTINDIA, BSE: 500488) traded higher in Friday’s session, riding a broader pharma-sector bid while investors also digested a fresh compliance update (trading-window closure) and revisited the company’s latest quarterly performance and Street forecasts. Around midday, Abbott India was quoted near ₹28,100–₹28,200, depending on venue and timestamp, with a market capitalisation in the ~₹59,700–₹59,800 crore range. Business Standard+1 Abbott India stock: what’s moving the price on 19 December 2025? Two big currents shaped sentiment for pharma counters on December 19: 1) Sector tailwinds from the “Biosecure Act” narrativePharma stocks were in
19 December 2025
·····
Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

December 18, 2025 — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back in the spotlight after a sharp two-day move that pushed the stock back to the $2.5 area—still far below where many Wall Street price targets sit, but enough to reignite the “is this finally a bottom?” debate around one of biotech’s most volatile commercial launches. According to Investing.com’s recent trading history, IOVA jumped 12% on Wednesday, December 17, closing at $2.52 on 23.27 million shares after already rising on December 16. Investing.com As of December 18, the stock continued to trade around $2.52, with a recent 52-week range of
18 December 2025
·····
1 2 3 4 5 6 … 9

Stock Market Today

Halma share price: Friday’s lift sets up what investors watch next week

Halma share price: Friday’s lift sets up what investors watch next week

7 February 2026
Halma shares closed up 0.7% at 3,548 pence on Friday, valuing the group at about £13.4 billion. The Bank of England held rates at 3.75% in a split vote, keeping rate-cut speculation in focus. Halma’s next trading update is set for March 12. The FTSE 100 ended the week up 0.6%, lifted by bank stocks.
Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop